SCHEMBL5606504

SCHEMBL5606504

COc1ccccc1Oc1ccc(-c2ccsc2)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAK O14976 1/20 0.50
PDGFRB P09619 1/20 0.47
PDGFRA P16234 1/20 0.47
ERN1 O75460 1/20 0.46
TACR1 P25103 1/20 0.43
CYP2A6 P11509 2/20 0.43
STK10 O94804 2/20 0.43
SLK Q9H2G2 2/20 0.43
CYP2E1 P05181 1/20 0.43
CYP2B6 P20813 1/20 0.43
PTPRC P08575 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TUBB4A P04350 2/20 0.41
TUBB P07437 2/20 0.41
TUBA3C P0DPH7 2/20 0.41
TUBA1B P68363 2/20 0.41
TUBA4A P68366 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26414634 0.77 ERN1 (0.50) GAKPDGFRBPDGFRAERN1CYP2A6
SCHEMBL5992568 0.77 GAK (0.48) GAKPDGFRBPDGFRAERN1CYP2A6
SCHEMBL4444229 0.76 MEN1 (0.51) GAKPDGFRBPDGFRAERN1CYP2A6
SCHEMBL8526954 0.76 PDGFRB (0.61) GAKPDGFRBPDGFRAERN1CYP2A6
SCHEMBL27703952 0.76 ERN1 (0.49) GAKPDGFRBPDGFRAERN1CYP2A6
SCHEMBL5607368 0.75 ERN1 (0.45) PDGFRBPDGFRAERN1CYP2A6CYP2E1
SCHEMBL29234155 0.74 ERN1 (0.58) PDGFRBPDGFRAERN1CYP2A6ALDH1A1
SCHEMBL8840880 0.73 PDE4A (0.67) PDGFRBPDGFRAERN1ALDH1A1MAPK1
SCHEMBL4454628 0.73 FYN (0.56) PDGFRBPDGFRAERN1CYP2A6STK10
SCHEMBL30340102 0.73 FYN (0.56) PDGFRBPDGFRAERN1CYP2A6STK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP disclosed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US disclosed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents TYR, NFE2L2, CYP1A1 GAK 1598/4885PDGFRB 3967/4885PDGFRA 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.